Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
KNSA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KNSA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 54.6% | 11.4% | 8.7% |
| 2024 | 85.6% | -10.8% | -10.2% |
| 2023 | 79.1% | -9.3% | 5.2% |
| 2022 | 89.6% | 4.4% | 83.3% |
| 2021 | 76.4% | -406.4% | -409.7% |
Download Data
Export KNSA earnings history in CSV or JSON format
Free sign-in required to download data
Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings Overview
As of May 7, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) reported trailing twelve-month net income of $73M, reflecting +225.0% year-over-year growth. The company earned $0.89 per diluted share over the past four quarters, with a net profit margin of 8.7%.
Looking at the long-term picture, KNSA's historical earnings data spans multiple years. The company achieved its highest annual net income of $183M in fiscal 2022.
Kiniksa Pharmaceuticals, Ltd. maintains positive profitability with a gross margin of 54.6%, operating margin of 11.4%, and net margin of 8.7%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ARDX (-$58M net income, -15.1% margin), PRAX (-$303M net income), RCUS (-$369M net income, -142.9% margin), KNSA has outperformed on profitability metrics. Compare KNSA vs ARDX →
KNSA Earnings vs Peers
Earnings metrics vs comparable public companies
KNSA Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $59M | +236.6% | $77M | $0.75 | 8.7% | 11.4% |
| 2024 | -$43M | -406.7% | -$46M | $-0.60 | -10.2% | -10.8% |
| 2023 | $14M | -92.3% | -$25M | $0.20 | 5.2% | -9.3% |
| 2022 | $183M | +216.1% | $10M | $2.60 | 83.3% | 4.4% |
| 2021 | -$158M | +2.1% | -$157M | $-2.30 | -409.7% | -406.4% |
| 2020 | -$161M | +0.3% | -$157M | $-2.61 | - | - |
| 2019 | -$162M | -56.8% | -$170M | $-2.99 | - | - |
| 2018 | -$103M | -59.1% | -$108M | $-3.49 | - | - |
| 2017 | -$65M | -170.6% | -$65M | $-2.00 | - | - |
| 2016 | -$24M | - | -$24M | $-0.74 | - | - |
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KNSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
Is KNSA growing earnings?
KNSA EPS is $0.89, with earnings growth accelerating to +225.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $73M.
What are KNSA's profit margins?
Kiniksa Pharmaceuticals, Ltd. net margin is +8.7%, with operating margin at +11.4%. Margins sit within typical range for the sector.
How consistent are KNSA's earnings?
KNSA earnings data spans 2016-2025. The accelerating earnings trend is +225.0% YoY. Historical data enables comparison across business cycles.